PI3K Inhibition in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

No abstract available
Source: Oncology Times - Category: Cancer & Oncology Tags: News Source Type: research

Related Links:

Authors: Gui W, Li J, Zhang Z, Wang L, Zhao J, Ma L, Su L Abstract The present case report investigated the clinical characteristics of primary hematological malignancy of the uterine cervixin five patients. Among the five patients, three patients were diagnosed with non-Hodgkin's lymphoma (NHL) and two patients with myeloid sarcoma (MS) of the uterine cervix. Biopsies of the uterine cervices demonstrated the involvement of lymphoid cells or myeloid blasts cells. Immunohistochemical staining demonstrated the expression of B-lymphoid and myeloid lineage markers. The associated lysozyme, myeloperoxidase and mast/stem...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Harkins RA, Chang A, Patel SP, Lee MJ, Goldstein JS, Merdan S, Flowers CR, Koff JL Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and is an aggressive malignancy with heterogeneous outcomes. Diverse methods for DLBCL outcomes assessment ranging from clinical to genomic have been developed with variable predictive and prognostic success. Areas covered: The authors provide an overview of the various methods currently used to estimate prognosis in DLBCL patients. Models incorporating cell of origin, genomic features, sociodemographic factors, treatment eff...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Lymphoma, Non-Hodgkin;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma Intervention:   Biological: CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Sponsor:   Shanghai Ming Ju Biotechnology Co., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Lymphoma, Non-Hodgkin Intervention:   Drug: CC-95775 Sponsor:   Celgene Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
High dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (AHSCT) is the standard of care in first-line treatment for eligible mantle cell and most T-cell Non-Hodgkin lymphoma (NHL) and in primary refractory or relapse NHL [1 –3]. Over the last two decade transplant programs have seen a significant increase in the median age of AHSCT recipients [7]. Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) revealed that the percentage of AHSCT in patients ≥ 60 years old has increased from 1 0% between 2000-2006 to 22% between 2007-2015.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The phase 1/2 clinical trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) involvement, due to strict eligibility criteria. Here, we report on our institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel. No patient experienced greater than grade 1 neurotoxicity, and no patient required tocilizumab or steroids for CAR T-cell–mediated toxicities. Biomarke...
Source: Blood - Category: Hematology Authors: Tags: Immunobiology and Immunotherapy, Lymphoid Neoplasia, Brief Reports, Clinical Trials and Observations Source Type: research
AbstractPrimary Sj ögren syndrome (pSS) is usually a mild disease, but serious complications such as non-Hodgkin lymphoma—and hypothetically other malignancies—may develop. The aim of this study was to evaluate both overall and specific incidence of cancer in a cohort of patients with pSS compared to the expected incidence in general population of Argentina. Retrospective analytic study of pSS patients fulfilling American-European Consensus Group (AECG) criteria, followed from the time of their diagnosis until the end of the study, death, loss of follow- up, or being given a diagnosis of cancer. Cancer inc...
Source: Rheumatology International - Category: Rheumatology Source Type: research
CONCLUSION: 90Y-IT consolidation and rituximab maintenance were similar with respect to PFS, OS, and TTNT. However, the features and grades of adverse effects significantly differed. Patient-specific characteristics should be considered when deciding post-remission treatments. PMID: 31496425 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Conditions:   Non-Hodgkin Lymphoma;   Follicular Lymphoma;   DLBCL;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma Intervention:   Drug: IGM-2323 Sponsor:   IGM Biosciences, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Lymphoma | Non-Hodgkin's Lymphoma